In a similar fashion, the selection of HER2-amplified breast cancer patients for trastuzumab therapy and estrogen receptor (ER)-positive patients for tamoxifen therapy represented an extension of the concept to solid tumors (3). This evidence concerns the gene ESR1 and breast carcinoma.